2171.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

Stats
Dagens volum	1.18M
Gjennomsnittsvolum	1.27M
Markedsverdi	3.14B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-3.76
ATR14	HKD0.0120 (0.22%)

Volum Korrelasjon

Lang: -0.16 (neutral)

Kort: 0.51 (weak)

Signal:(68.015) Neutral

CARsgen Therapeutics Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CARsgen Therapeutics Korrelasjon - Valuta/Råvare

0.40
( neutral )

0.75
( moderate )

0.00
( neutral )

-0.70
( moderate negative )

0.28
( neutral )

0.20
( neutral )

CARsgen Therapeutics Økonomi

Annual	2023
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-1.340

FY	2023
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-1.340

FY	2022
Omsetning:	HKD0
Bruttogevinst:	HKD0 (0.00 %)
EPS:	HKD-1.620

FY	2021
Omsetning:	HKD25.81M
Bruttogevinst:	HKD25.81M (100.00 %)
EPS:	HKD-8.36

Financial Reports:

No articles found.

CARsgen Therapeutics

CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.